Tongyuankang Pharmaceutical (同源康医药) is an innovative drug developer that has built platforms for targeted small‑molecule design and screening, deuterated drug R&D, and large‑molecule immunotherapy. The company is focused on cancer treatment and anti‑cancer drug development. It recently completed a D‑round financing of nearly RMB 200 million. The round was led by Huiyu Pharmaceutical with participation from a CICC Capital‑affiliated fund, Changxing JinKong, and the Huzhou Talent Fund. KaiCheng Capital served as the company's financial advisor on the transaction. The financing supports the company's continued R&D efforts in oncology. Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., founded in November 2017, is an innovation-focused biopharma concentrating on anti-tumor small-molecule Best-in-class/First-in-class drug development with R&D centers in Changxing, Zhengzhou and Shanghai. The company has built a 6,000 sqm new-drug R&D center in Changxing and a global-caliber R&D and management team led by Dr. Wu Yusheng, including national- and provincial-level experts, over ten returnee PhDs and about ten clinical experts. Within roughly 30 months the team completed two Class 1 IND filings and initiated Phase I trials; its core candidate TY9591, positioned against osimertinib, has shown superior preclinical and early clinical efficacy and safety and is being developed for brain-metastasis indications. Two additional novel-target programs are expected to file INDs in China and the U.S. soon, and multiple international-leading small-molecule programs are in preclinical/clinical preparation. The company plans to advance late-stage clinical development and expand manufacturing capability to support global development and future commercialization. TongyuanKang Pharmaceutical concentrates on discovery and development of anti‑tumor small‑molecule Best‑in‑class/First‑in‑class therapies. The company operates a 6,000 sqm new drug R&D center in Zhejiang Changxing Life Science Park and maintains clinical and business development functions in Shanghai. Its team includes over ten returnee PhD experts, designated provincial experts and six clinical experts, and has progressed multiple compounds into IND and clinical stages. Since formation, the team completed two class‑1 IND filings and initiated clinical trials; two novel‑target programs reached PCC stage and one candidate has been licensed out. The company intends to use new funds to advance two class‑1 innovative drugs through clinical development, prepare multiple international‑leading small‑molecule preclinical IND filings, and further develop follow‑on pipeline projects. Financially, TongyuanKang has completed multiple financings and reports total funding exceeding RMB 400M to date.

Total raised

$130M

Funding rounds

3

Latest round

Series D

Latest activity

Dec 2023